RxDoctor Payments Data

Lori Brent

Family · Jackson, MSNPI 1992958169

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.6% of the total across 590 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,167, 2.5 times the $1,250 reported in 2021. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,459in general payments, 2019–2025

Across 590 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Merck$672
  • Genentech USA, Inc.$584
  • AstraZeneca$578
  • Gilead$519
  • Pfizer$472
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,38491%
  • Education$4424%
  • Other$6326%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$1,603
Merck33$672
Genentech USA, Inc.35$584
AstraZeneca37$578
Gilead(2 entities)25$519
Pfizer31$472
Bristol Myers Squibb25$458
Amgen20$453
Sanofi22$424
Johnson & Johnson28$405
Incyte Corporation22$343
Daiichi Sankyo Inc.12$295
Takeda Pharmaceuticals U.S.A., Inc.15$285
AbbVie11$276
Lilly USA, LLC15$265
Deciphera Pharmaceuticals Inc.11$225
Astellas Pharma US Inc12$205
AVEO Pharmaceuticals, Inc.7$205
Beigene USA, Inc.10$195
E.r. Squibb & Sons, L.L.C.11$194
Stemline Therapeutics Inc.8$190
Rigel Pharmaceuticals, Inc.9$159
Tersera Therapeutics LLC5$150
Pharmaessentia USA Corporation6$143
EMD Serono, Inc.7$139
Sanofi-aventis U.S. LLC3$127
Sobi, Inc5$125
Ipsen Biopharmaceuticals, Inc5$116
Seagen Inc.7$115
Pharmacyclics LLC, An Abbvie Company8$115
Eisai Inc.6$107
Bayer4$97
Puma Biotechnology, Inc.6$94
GSK5$89
Mirati Therapeutics, Inc.5$87
Blueprint Medicines Corporation5$82
Karyopharm Therapeutics Inc.5$77
Array Biopharma Inc4$72
Regeneron Healthcare Solutions, Inc.3$58
Jazz Pharmaceuticals Inc.3$57
Apellis Pharmaceuticals, Inc.4$57
Boehringer Ingelheim3$53
Taiho Oncology, Inc.2$41
Exelixis Inc.2$40
Genmab U.S., Inc.2$33
Coherus Oncology, Inc.2$33
G1 Therapeutics, Inc.2$32
Morphosys, US Inc.1$31
Janssen Scientific Affairs, LLC1$28
Pharmacosmos Therapeutics Inc.1$28
Springworks Therapeutics, Inc.1$23
Sanofi US Services Inc.1$23
Adaptive Biotechnologies Corporation1$22
Sanofi Pasteur Inc.1$19
Recordati_rare_diseases_inc.1$19
Iovance Biotherapeutics, Inc.1$19
Legend Biotech USA Inc.1$18
Servier Pharmaceuticals LLC1$16
Pharming Healthcare, Inc.1$16
Novocure Inc.1$15

How this compares

$11,459 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,271
Medicare patients
30
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib13$177,979
EliquisApixaban46$28,985
Imatinib Mesylate13$14,731
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen147$3,803
Abiraterone Acetate11$3,076
Fentanyl28$2,622
Anastrozole93$1,678
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$1,034
Letrozole39$858
Megestrol Acetate13$778
Colesevelam Hcl11$748
Dexamethasone20$596
Morphine Sulfate ErMorphine Sulfate16$583
Omeprazole25$344
Oxycodone Hcl11$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$265$177,97913 claims
PfizerEliquis$472$28,98546 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$28$3,07611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →